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Aims Symptoms of anxiety and depression often co-exist with cardiovascular disease, yet little is known about the
prospective risk for heart failure (HF) in people with symptoms of depression and anxiety. We aimed to study these
prospective associations using self-reported symptoms of anxiety, depression, and mixed symptoms of anxiety and
depression (MSAD) in a large population sample.
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Methods
and results
In the second wave of the Nord-Trøndelag Health Study (HUNT 2, 1995–1997), Norway, baseline data on symptoms
of anxiety and depression, socio-demographic variables, health status including cardiovascular risk factors, and
common chronic somatic diseases were registered for 62 567 adults, men and women, free of known HF. The cohort
was followed for incident HF from baseline throughout 2008. A total of 1499 cases of HF occurred during a mean
follow-up of 11.3 years (SD= 2.9), identified either in hospital registers or by the National Cause of Death Registry.
There was no excess risk for future HF associated with symptoms of anxiety or MSAD at baseline. For depression,
the multi-adjusted hazard ratios for HF were 1.07 (0.87–1.30) for moderate symptoms and 1.41 (1.07–1.87) for
severe symptoms (P for trend 0.026). Established cardiovascular risk factors, acute myocardial infarction (AMI) prior
to baseline, and adjustment for incident AMI as a time-dependent covariate during follow-up had little influence on
the estimates.
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Conclusion Symptoms of depression, but not symptoms of anxiety or MSAD, were associated with increased risk for HF in a
dose–response manner. The increased risk could not be fully explained by cardiovascular or socio-economic risk
factors, or by co-morbid AMI.
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Introduction
Heart failure (HF) is often co-prevalent with symptoms of
depression1–8 and anxiety,3,9 and symptoms of depression have
been found to worsen the course and prognosis of established
HF.2,3,10
Ischaemic heart disease (IHD), like acute myocardial infarction
(AMI), is the main cause of HF in Europe and accounts for ∼60% of
HF.11 Other known precursors for HF are hypertension, diabetes,
cardiomyopathy, heart valve disease, and arrhythmias.12 In the
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.. development of HF, except HF initiated by AMI, the process of
myocardial remodelling often starts long before the onset of HF
symptoms.13 As HF is a major and increasingly important public
health problem, it is crucial to search for modifiable risk factors in
the aetiology of HF.14 It is plausible that symptoms of depression
and anxiety represent such modifiable risk factors as they have
been found to influence behavioural risk factors for HF, such as
obesity, reduced physical activity, alcohol abuse, and smoking.1,15
Furthermore, neurohormonal stress associated with symptoms of
depression and anxiety is known to regulate blood pressure, heart
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rate, proinflammatory cytokines, and circulating catecholamine
levels, which in turn promote HF.1,16
However, the prospective evidence supporting a link between
symptoms of depression and future HF arise from small studies of
elderly people, and the results are conflicting.4–8 To the best of our
knowledge, only one study, among US veterans, has investigated
the risk for future HF with symptoms of anxiety.17 We therefore
aimed to investigate the prospective association of self-reported
symptoms of anxiety and depression with risk for future HF in a
large population-based study, taking into account a large number
of established cardiovascular risk factors, previous and/or incident
AMI, several chronic somatic disorders, and previous symptoms of
anxiety and depression.
Methods
Study population and setting
All adult citizens in Nord-Trøndelag County, Norway, received a postal
invitation to participate in the second wave of the Nord-Trøndelag
Health Study (HUNT 2, 1995–1997, http://www.ntnu.edu/hunt). In
total, 94 187 individuals were invited, and 65 215 (69%) participated
in the HUNT 2 study. The participants attended a baseline clini-
cal examination and gave self-report on standardized questionnaires
(http://www.ntnu.edu/hunt/data/que). Details of the HUNT study have
been published elsewhere.18,19
The study was approved by the regional committee for medical and
health research ethics, by the National Directorate of Health, and by
the Norwegian Data Inspectorate.
Exposure: symptoms of anxiety
and depression
Participants self-reported symptoms of anxiety and depression
using a Norwegian version of the Hospital Anxiety and Depres-
sion Scale (HADS),20 which assesses core psychological symptoms
of anxiety (HADS-A) and depression (HADS-D) during the
previous week.
Seven depression questions mirror symptoms of anhedonia and loss
of interest, and seven anxiety questions mirror mostly symptoms of
worry and tension. We included all participants that responded to ≥5
items on one subscale (n= 62 693). For those who filled in only five or
six items on the HADS-A and -D subscales, missing scores were sub-
stituted based on the sum of completed items multiplied by 7/5 or 7/6,
respectively.21 All HADS questions have a 4-point Likert scale, ranging
from 0 (no symptom) to 3 (highest symptom level); thus the subscales
range from 0 points (no symptoms) to 21 points, which allows calcula-
tion of risk per unit increase in the HADS.21 In addition, recommended
cut-offs were used to categorize the participants as not depressed or
anxious (score <8), moderately depressed or anxious (score between
8 and 11), and severely depressed or anxious (score ≥11).22 Mixed
symptoms of anxiety and depression (MSAD) were calculated by
summing up valid HADS-A and HADS-D into HADS-total scores
(HADS-T) and categorized into no MSAD (score <15), moderate
MSAD (score between 15 and 18), and severe MSAD (score ≥19).23
Previous symptoms of MSAD were available for 36 418 participants
that also attended HUNT 1 (1984–1986) and filled in the 4-item
Anxiety and Depression Index (ADI-4). ADI-4 has a high correlation
(0.83) with the HADS-T score from HUNT 2 and is an acceptable ..
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.. indicator for MSAD (sensitivity 0.51, specificity 0.93).24 Two ADI
questions have a 4-point Likert scale: calmness, ranging from almost
all the time (1) to never (4); and nervousness, ranging from never (1)
to almost all the time (4). The last two ADI questions about mood and
vitality have a 7-point Likert scale ranging from very happy/strong and
fit (1) to very downhearted/tired and worn out (7). We categorized
symptoms of MSAD in HUNT 1 by scoring on the upper quartile
on ADI-4, i.e above a score of 14. Symptoms of MSAD in HUNT 2
were defined as a score ≥19 on the HADS-T subscale. A variable
to indicate the combined burden of MSAD in HUNT 1 and 2 was
created in categories of never (no symptoms of MSAD in HUNT 1
or 2), one (MSAD symptoms in one of the HUNT waves), and two
episodes (MSAD symptoms in both HUNT waves).
Outcome ascertainment
After baseline, the participants were followed up for a first incident
of HF until 31 December 2008, identified either by linkage with med-
ical records at the two hospitals in Nord-Trøndelag county or by the
National Cause of Death Registry.25 A total of 126 participants were
excluded because their medical records indicated HF before they par-
ticipated at baseline. Therefore, 62 567 people were included in the
analyses, as displayed in Figure 1. Heart failure was defined and diag-
nosed according to the current European Society of Cardiology (ESC)
Guidelines.26 The overall quality of the hospital discharge diagnosis of
HF is generally high in Nordic countries.27,28 In order to increase speci-
ficity, we only extracted primary diagnoses as recommended.27 Deaths
due to HF were extracted from the National Death Registry. We used
International Classification of Diseases (ICD) 9 code 428 and ICD
codes I50.0, I50.1, and I50.9 to identify HF.25 Having 100% specificity
and low—but non-differential—sensitivity leads to no bias of the risk
ratio. Even a slight decrease in specificity, even if non-differential, might
lead to a severe bias. Therefore, in brief, our decision to include only
primary diagnosis decreases our power, but preserved our validity.29
During an average of 11.3 years of follow-up, 8164 participants who
died of causes other than HF and 224 who left the county were
censored at time of death or emigration (see Figure 1).
Covariates
Demographic and lifestyle factors
Cohabitation status was dichotomized as living with a partner or alone.
Education was categorized as low (≤9 years), medium (between 10 and
12 years), or high (over 12 years).
Smoking habits were self-reported and were categorized as current,
previous, or never smoking. We categorized the participants according
to self-reported alcohol consumption as abstainers, very light drinkers
(0–1 drinks per day), light to moderate drinkers (1–2 drinks per day),
or moderate to heavy drinkers (>2 drinks per day). Physical activity
was reported as light or hard, defined respectively as activity excluding
or including sweating or feelings of breathlessness. The participants
were categorized as inactive (<1 h of strenuous activity and <3 h of
light physical activity per week), moderately active (1–3 h of strenuous
activity or >3 h of light activity per week), and as physically active (>3 h
of strenuous physical activity per week).
Common chronic somatic diseases
The participants reported their medical history (yes/no) regarding pre-
vious cardiovascular diseases (myocardial infarction, stroke, or angina
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Flow chart of the heart failure (HF) study recruitment and follow-up.
pectoris), cancer, asthma, diabetes mellitus, other endocrine disorders
(hypothyreosis, hyperthyreosis, goitre, or thyroiditis), musculoskeletal
disorders (osteoporosis, fibromyalgia, or arthrosis/arthritis), autoim-
mune disease (Bechterew disease or rheumatoid arthritis), epilepsy,
or other chronic disease. Those who answered ‘yes’ to one or more
of these questions were categorized as having a chronic disease.
Clinical examination
Clinical examinations were performed by trained nurses according to a
standardized protocol and included measurements of blood pressure,
heart rate, weight, height, and waist and hip circumference. Heart rate,
and systolic and diastolic blood pressures were measured after the
participant had been seated for at least 2min with the cuff on, with cuff
size adjusted for arm circumference.30 Blood pressure and heart rate
measurements were performed with the Dinamap 845XT (Criticon)
based on oscillometry and automatically involved three recordings at
1-min intervals. The first heart rate recording was on average 2 b.p.m.
lower than the second and third measurement and was thus used
in order to mirror resting heart rate. For blood pressure, the value .
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.. decreased for each recording, thus we used the average of the second
and third blood pressure readings. Height was measured without shoes
to the nearest 1.0 cm and weight with light clothing to the nearest
0.5 kg.30 Body mass index (BMI) was computed as weight (in kg) divided
by the squared value of height (in metres).
Blood sampling and laboratory measurements
A non-fasting whole blood sample was drawn from each partici-
pant, recording the time between the last meal and the venepunc-
ture. Serum was separated by centrifugation at the screening site
and immediately placed in a refrigerator. The samples were sent (the
same day, or the following Monday for samples drawn on Friday)
for analyses at the central laboratory at Levanger Hospital, Nor-
way, where a Hitachi 911 Autoanalyzer was used, applying reagents
from Boehringer Mannheim, Germany. Serum total cholesterol was
measured by an enzymatic colorimetric cholesterol esterase method
and serum creatinine by the Jaffé method. The day-to-day coeffi-
cient of variations were 1.3–1.9% for total cholesterol and 3.5% for
creatinine.8
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Statistical analysis
We used Cox proportional hazard models to examine the associations
of symptoms of depression and anxiety with subsequent risk for HF
and hazard ratios (HRs) with 95% confidence intervals (CIs). All the
models were analysed both using a categorical approach and estimating
risk per unit increase on the different HADS scores. For test of trends
between increasing anxiety and depression symptom level, a numeric
value of 0–2 was assigned to the HADS categories, with 0 having
no, 1 having moderate, and 2 having severe symptoms of anxiety
or depression, treating the categories as a continuous variable. In a
separate analysis, we calculated the risk for HF associated with the
presence of MSAD in HUNT 1 and HUNT 2 when those without
symptoms of MSAD in both of the surveys constituted the reference
group.
We used directed acyclic causal graphs to summarize visually hypo-
thetical relationships among variables of interest.29 Model 1, adjusted
for age as a continuous variable and sex, is the best for assessing causal-
ity. Models 2–5 include variables that may act as both confounding and
mediating factors for the association of depression and anxiety with HF
risk. Model 2 included potentially socio-economic confounders, such
as education and marital status. In model 3, established cardiovascular
risk factors such as high heart rate, high blood pressure, low physical
activity, high BMI, smoking, dyslipidaemia, alcohol intake, diabetes mel-
litus, and serum creatinine were added. Model 4 tested whether AMI
prior to baseline data collection influenced the estimates. Finally, the
full multivariable model tested if AMI during follow-up influenced the
estimates, and included AMI during follow-up as a time-dependent vari-
able (model 5). For the 2522 non-responders on the HADS question-
naire, we examined HF incidence and the distribution of the variables
included in the statistical models.
Several stratified analyses were conducted to assess whether the
association of anxiety and depression and risk for HF could be modified
by other factors. We investigated the potential effect of modification
by sex, age (dichotomized at age 50 and age 65), BMI (dichotomized at
≥35 kg/m2), total cholesterol (dichotomized at 6.5mmol/L), education
(dichotomized at 12 years), blood pressure (systolic blood pressure
dichotomized at >140mmHg, diastolic blood pressure at >90mmHg),
smoking status (current vs. no current smoking), alcohol consumption
(heavy drinking vs. no heavy drinking), and previous AMI (yes/no). We
also formally tested the homogeneity of stratum-specific relative risks.
For these tests of interaction, we used the trend variable as defined
above.
Several sensitivity analyses were performed to assess the robustness
of our findings. First, as AMI is a known risk factor for HF and is also
associated with depression and anxiety symptoms, we performed an
additional analysis restricted to those without known AMI at baseline.
Next, we analysed the risk restricted to diabetic patients. Thereafter,
we excluded participants with one or more of the following co-morbid
physical illnesses: previous myocardial infarction (AMI), stroke, angina
pectoris, cancer, asthma, diabetes mellitus, other endocrine disorders,
musculoskeletal disorders, autoimmune diseases, and other chronic
diseases.
Secondly, in additional analysis, we restricted cases to those HF
cases that were confirmed at the hospital; thus, cases whose HF
diagnosis were based on death certificates alone were excluded from
the analyses.
Finally, in order to address the possibility of reverse causation
as an explanation for possible associations, we excluded the first 5
years of follow-up and repeated the analyses. All sensitivity analyses
were run in the full multivariable model including previous AMI and ..
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.. adjustment for incident AMI during follow-up as a time-dependent
covariate.
We tested the proportionality of hazard using log–log curves
and formal tests of interaction with time or log-time. There was
no evidence against the proportionality assumption in our models.
Statistical analyses were performed in Stata IC/12.1 for Windows
(©Stata Corp LP).
Results
Characteristics of the study population at baseline, by HF status
during follow-up, are shown in Table 1. Among those who did
not respond to the HADS questionnaire, the HF incidence in
the 11.4 years was 8.7%, probably mainly because they were
older (mean 66.4 years) at baseline, and in addition had a more
unfavourable cardiovascular risk profile, including higher blood
pressure on average, than the total study population. Among
the 63 567 study participants, 1499 participants (2.4%) developed
HF during an average of 11.3 years (SD 2.9) of follow up. Of
these, 1245 HF cases were diagnosed and included in the hospital
registers, and 254 were registered by the National Cause of Death
Registry alone. The participants that developed HF were older
at baseline examination and more likely to have diabetes, higher
systolic and diastolic blood pressure, be inactive, to live alone, have
lower education, be alcohol abstainers, and score higher on the
HADS-D subscale. They also had a higher incidence of incident
AMI (14%) during follow-up, compared with those who did not
develop HF (2.5% incident AMI).
Using the highest cut-off (HADS ≥11), the prevalence rates
were 3.2% and 5.1% for depression and anxiety symptoms, respec-
tively. This estimate is comparable with the prevalence of diag-
nosed depression and anxiety disorders in the general population
in Europe.31 These participants were more likely to be female,
less educated, inactive, current smokers, alcohol abstainers, and
report a history of previous AMI than those in the reference
group.
Table 2 presents the age- and sex-adjusted HRs and several
multivariable adjusted HRs for incident HF in relation to symptoms
of depression, anxiety, and MSAD. There was no excess risk
for future HF associated with symptoms of anxiety in the crude
model, adjusted for sex and age (HR 1.17, 95% CI 0.90–1.15).
For MSAD, the moderately increased risk for HF observed in
model 1 (HR 1.34, 95% CI 1.04–2.07) was explained by traditional
cardiovascular factors in model 3 (HR 1.09, 95% CI 0.81–1.46).
For depression, the age- and sex-adjusted HRs for HF were 1.11
(0.95–1.30) for moderate symptoms and 1.46 (1.19–1.80) for
severe symptoms (P for trend 0.000). These associations for severe
symptoms were only slightly attenuated after further adjustments
for socio-economic status, an established cardiovascular risk factor
(HR 1.37, 95% CI 1.04–1.81). Additional adjustment for previous
and time-dependent incident AMI during follow-up did not further
attenuate the risk for HF associated with severe symptoms of
depression (HR 1.41, 95% CI 1.07–1.87). The results from the
analysis using the risk per unit HADS score approach did not differ
from the categorical approach; taking HADS-D as an example, with
a 1.03 increased risk associated with each unit rise in HADS-D
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics of the participants according to heart failure during follow-up
n HF during follow-up, % (n) No HF during follow-up, % (n)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total 62 567 2.4 (1499) 97.6 (61 068)
Variable
Sex (male) 62 567 50.6 (759) 46.7 (28 559)
Diabetes mellitus 62 448 12.7 (188) 2.6 (1562)
Smoking 62 344
Never 28 313 45.4 (674) 45.4 (27 639)
Former 15 675 32.7 (485) 24.9 (15 190)
Current 18 356 21.9 (1485) 29.6 (18 030)
Physical activity 56 993
Inactive 22 255 60.9 (676) 38.6 (21 579)
Moderately active 29109 34.7 (385) 51.4 (28 724)
Physically active 5629 4.4 (49) 9.9 (5580)
Living alone 62 425 43.9 (659) 39.4 (24 007)
Education 60 270
≤9 years 21 629 71.6 (942) 35.1 (20 687)
10–12 years 26 443 22.4 (295) 44.4 (26 148)
>12 years 12 198 5.9 (78) 20.6 (12 120)
Alcohol 58,986
Abstainer 23 640 71.2 (975) 39.3 (22 665)
Light drinker 27 298 23.7 (325) 46.8 (26 973)
Moderate drinker 6196 3.8 (52) 10.7 (6144)
Heavy drinker 1852 1.2 (17) 3.2 (1835)
Previous myocardial infarction 1871 21.7 (322) 2.5 (1549)
Myocardial infarction during follow-up 1739 14.0 (210) 2.5 (1529)
Variables, mean (SD) n Mean (SD) Mean (SD)
Age, years 62 567 73.6 (9.7) 48.7 (16.6)
BMI, kg/m2 61 956 27.9 (4.6) 26.3 (4.1)
Heart rate, b.p.m. 62 235 73.3 (14.6) 71.3 (13.1)
Systolic BP, mmHg 62152 156.6 (25.9) 136.9 (21.2)
Diastolic BP, mmHg 62152 85.5 (12.1) 80.0 (12.0)
Total cholesterol, mmol/ L 62 216 6.4 (1.3) 5.9 (1.3)
HDL cholesterol, mmol/L 62 195 1.3 (0.4) 1.4 (0.4)
Triglycerides, mmol/L 62 215 2.1 (1.2) 1.7 (1.1)
Serum creatinine, mmol/L 62 214 97.6 (22.6) 87.5 (15.0)
HADS-Depression score 62 414 4.6 (3.5) 3.5 (3.3)
HADS-Anxiety score 61 335 3.8 (3.4) 4.3 (3.3)
HADS-Total score 61182 8.4 (6.0) 7.7 (5.6)
ADI-Total score in HUNT 1 36 418 13.6 (1.3) 13.5 (1.2)
ADI, Anxiety and Depression Index; BMI, body mass index; BP, blood pressure; HADS, Hospital Anxiety and Depression Scale; HF, heart failure.
score, a person with a score of 8 will have 1.039 times, i.e 30%,
increased risk compared with a person that scores 0. Figure 2 shows
the Kaplan–Meier curves for incident HF according to depression
symptom categories; depressive symptoms were associated with
higher risk for HF in a dose–response manner consistently during
the follow-up.
Table 3 displays the risk for HF with MSAD in HUNT 1 and
2. Those who reported MSAD in both HUNT 1 and 2 had an
HR of 1.47 (95% CI 1.04–2.07) for HF in model 1 compared
with those who did not experience MSAD in any of the health
surveys. This relative risk for HF was, however, largely explained by
cardiovascular risk factors (HR 1.18, 95% CI 0.73–1.87). Further
adjustments for previous AMI and time-dependent incident AMI
during follow up did not lead to further attenuation. ..
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. We found no statistical evidence for any effect modification for
any of the stratified variables including sex, age, education, smoking
status, BMI, total cholesterol, physical activity, and blood pressure.
Sensitivity analysis
Supplementary material online, Table S1 presents the multivariable
adjusted HRs for HF in relation to symptoms of depression, anxiety,
and MSAD in different sensitivity analyses.
A total of 52 202 participants completed the questionnaire on
common chronic somatic disease. Of these, 16 072 reported hav-
ing at least one chronic somatic disease. Diabetes was six-fold
more prevalent in those who later developed HF, and this war-
ranted a separate analysis; in the 1750 diabetic participants, ≥11
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Hazard ratios (95% confidence intervals) for heart failure during follow-up according to symptoms of
depression and anxiety, and mixed symptoms of anxiety and depression in HUNT 2 (1995–1997).
Variable Model 1 Model 2 Model 3 Model 4 Model 5
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HADS-D Events/person-years 1492/703 766 1310/679 612 905/597 200 900/596 685 900/596685
0–7 Reference Reference Reference Reference Reference
8–10 1.11 (0.95–1.30) 1.10 (0.93–1.30) 1.07 (0.87–1.32) 1.07 (0.87–1.31) 1.08 (0.88–1.33)
≥11 1.46 (1.19–1.80) 1.51 (1.21–1.89) 1.38 (1.04–1.83) 1.41 (1.06–1.86) 1.41 (1.07–1.87)
P for trend 0.000 0.001 0.034 0.028 0.023
Risk per unit increase in the
HADS-D scale
1.03 (1.02–1.05) 1.03 (1.02–1.05) 1.03 (1.01–1.05) 1.03 (1.01–1.05) 1.03 (1.01–1.05)
HADS-A Events/person-years 1366/693 483 1224/671 888 869/593199 864/592 694 864/592694
0–7 Reference Reference Reference Reference Reference
8–10 1.12 (0.93–1.34) 1.15 (0.95–1.40) 0.88 (0.69–1.13) 0.88 (0.69–1.13) 0.90 (0.70–1.15)
≥11 1.17 (0.90–1.15) 1.07 (0.80–1.43) 0.95 (0.67–1.35) 0.98 (0.69–1.40) 1.00 (0.70–1.43)
P for trend 0.105 0.221 0.431 0.560 0.643
Risk per unit increase in the
HADS-A scale
1.01 (0.99–1.03) 1.01 (0.99–1.02) 1.01 (0.99–1.03) 1.01 (0.99–1.03) 1.01 (0.99–1.03)
HADS-T Events/person-years 1359/691 950 1219/670 617 868/592 540 869/592 035 863/592035
0–15 Reference Reference Reference Reference Reference
15–19 1.09 (0.90–1.33) 1.17 (0.91–1.37) 1.18 (0.92–1.49) 1.15 (0.90–1.46) 1.16 (0.91–1.48)
≥19 1.34 (1.04–2.07) 1.31 (1.04–1.66) 1.10 (0.82–1.48) 1.18 (0.87–1.58) 1.20 (0.89–1.61)
P for trend 0.018 0.015 0.248 0.151 0.114
Risk per unit increase in the
HADS-T scale
1.01 (1.00–1.02) 1.01 (1.00–1.02) 1.01 (0.99–1.02) 1.01 (1.00–1.02) 1.01 (1.00–1.03)
HADS, Hospital Anxiety and Depression Scale. HADS-T, was calculated by summing up valid HADS-A and HADS-D into HADS-total scores.
Model 1: adjusted for calendar age and sex.
Model 2: model 1+marital status, education.
Model 3: model 2+ smoking, physical activity, body mass index, total cholesterol, diabetes mellitus, resting heart rate, systolic blood pressure, alcohol, serum creatinine.
Model 4: model 3+ previous myocardial infarction.
Model 5: model 4+ time-dependent adjustment for acute myocardial infarction during follow-up.
Figure 2 Kaplan–Meier curve of incident heart failure during
follow-up according to depression category. HADS-D, Hospital
Anxiety and Depression Scale, depression subscale.
in depression score constituted a 70% (95% CI 1.03–2.80) higher
risk than for those who scored <8. This high risk in the diabetic
population was mainly explained by cardiovascular risk factors in
model 3, where the risk dropped to 23%. After exclusion of all
common chronic somatic diseases, 305 were diagnosed with HF
during follow-up, and the risk of HF in people free of chronic .
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. diseases related to symptoms of depression slightly increased. Of
special interest, the risk associated with symptoms of depression,
after excluding participants with self-reported previous AMI before
HUNT 2 (n=1253), was only reduced by ∼10% (HR 1.33, 95% CI
0.88–2.01) in the full multivariable model including adjustment for
time-dependent incident AMI during follow-up.
When follow-up was restricted to HF events confirmed in
hospitals (1073 events) and HF cases emerging after the first
5 years of follow-up (692 events), the risk for HF related to
symptoms of depression remained virtually unchanged. The risk
for HF associated with MSAD in HUNT 2 and repeated MSAD
in HUNT 1 and 2 was elevated in hospitalized confirmed HF
compared with the total HF sample, and lower after exclusion of
the first 5 years of follow-up.
Discussion
In this large prospective study of a general population free from
known HF at baseline, we found that symptoms of depression,
but not those of anxiety or MSAD, were associated with a
dose–response increased risk for incident HF. This risk remained
essentially unchanged after adjustment for demographic vari-
ables, established cardiovascular risk factors, previous AMI, and
time-dependent adjustment for incident AMI during follow-up. The
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Hazard ratios (95% confidence intervals) for heart failure during follow-up according to episodes of mixed
symptoms of anxiety and depressionin HUNT 1 and HUNT 2.
No. of episodes of MSAD Model 1 Model 2 Model 3 Model 4 Model 5 651/29616
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Events/person-years 1021/406071 910/392118 654/344 334 651/29 616
Never MSAD Reference Reference Reference Reference Reference
MSAD once 1.12 (0.98–1.27) 1.09 (0.95–1.24) 1.03 (0.88–1.20) 1.05 (0.89–1.22) 1.05 (0.90–1.23)
MSAD twice 1.47 (1.04–2.01) 1.53 (1.06–2.20) 1.30 (0.83–2.06) 1.21 (0.76–1.93) 1.21 (0.76–1.93)
P for trend 0.018 0.048 0.441 0.426 0.385
MSAD, mixed symptoms of anxiety and depression.
Model 1: adjusted for calendar age and sex.
Model 2: model 1+marital status, education.
Model 3: model 2+ smoking, physical activity, body mass index, total cholesterol, diabetes mellitus, resting heart rate, systolic blood pressure, alcohol, serum creatinine.
Model 4: model 3+ previous myocardial infarction.
Model 5: model 4+ time-dependent adjustment for acute myocardial infarction during follow-up.
association also remained robust in several additional sensitivity
analyses.
Comparison with previous studies
Previously, the association between anxiety symptoms and
future HF has been investigated in one study of American vet-
erans, where the authors found a 1.19 (95% CI 1.10–1.28)
increased age-adjusted hazard associated with anxiety disorders
and post-traumatic stress disorder.17 This point estimate is com-
parable with the 1.17 (95% CI 0.90–1.15) hazard for future HF
associated with a score of ≥11 on the HADS-A subscale in our
study. The US study has a larger sample size, with 236 079 partici-
pants, which may explain the difference in precision between the
two studies.
Symptoms of depression and risk for future HF have mostly
been investigated in smaller studies and/or in selected samples, and
conclusions have been conflicting.4–8,17 Two studies found negative
results between symptoms of depression and HF: the first of these
was the ‘Established population for epidemiologic studies of the
elderly’ (EPESE, n= 1749), conducted in 1999.5 However, in that
study, Chen et al. seem to have discarded symptoms of depression
as a risk factor for HF based on P-values from 𝜒2 and t-statistics,
which do not account for time to event. The second negative
results were reported in 2011 from ‘The cardiovascular health
study (CHS)’ population, who at baseline were on average 79 years
old but free of HF (n= 4114). Afro-American people reported
more depression (30%) compared with white people (18.7%)
in the CHS study, yet the distribution of confirmed HF events
between the ethnic groups was not reported. Based on well known
differences in health status and access to health services across
ethnical groups in the USA, this is a limitation of the otherwise
well performed study.32 In contrast, we had a homogenous study
population from Norway, where healthcare coverage is universal,
and free healthcare system access exists across socio-economic
groups.32
Conversely, three small-scale studies with potential methodolog-
ical problems reported increased risk for HF with depressive symp-
toms. ‘The Finland, Italy and Netherlands Elderly’ (FINE study), .
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.. which included only men (n= 799), found a 1.16 increased hazard
for each five steps in the Zung depression rating scale.6 Another
study, ‘the Systolic Hypertension in the Elderly Program’ in the
USA, had short follow-up of 4538 persons above 65 years with
hypertension,4 i.e inclusion of only persons predisposed for HF,7
found a 2.59 increased risk for future HF. The third study, also from
EPESE, found a 52% increased risk for future HF associated with
symptoms of depression, but only for the women in the sample. In
contrast, our study included a large community sample with both
sexes and long follow-up which allowed for exclusion of the first
5 years of follow-up, which increases the possibility of detecting
reverse causation. Further, we used statistical models that allowed
for time to event and we tested our model carefully for violations
against the proportionality of hazard assumptions.
Unfavourable socio-economic and behavioural lifestyles may be
a link between symptoms of depression and increased HF risk.
Symptoms of depression, but not as much symptoms of anxiety,
are often strongly associated with traditional risk factors for HF,
such as lower education, physical inactivity, unhealthy diet, obesity,
and poorer lifestyle.1,33,34 Some of these behaviours associated with
loweredmood, such as inactivity, obesity, and smoking, are also sug-
gested to be sources of an inflammatory process that can cause HF,
and reciprocally also cause depression.35 In our study, people with
the most severe symptoms of anxiety and depression had a more
unfavourable socio-economic and cardiovascular profile. However,
the adjustment for socio-economic factors and established cardio-
vascular risk factors only attenuated the relative risks in relation to
symptoms of anxiety and MSAD, but not for depressive symptoms.
Ischaemic heart disease is a major cause of HF, and IHD is closely
linked to symptoms of depression.36–38 However, in our analyses,
cardiovascular risk factors and AMI prior to baseline explained
only 10–13% of the risk point estimate for HF in association with
depressive symptoms. Time-dependent adjustment for incident
AMI during follow-up did not attenuate the risk any further. Other
chronic somatic diseases did not explain the association either, and
the risk for HF associated with symptoms of depression increased
when we excluded these chronic disorders. In diabetic patients,
for example, the crude risk for HF associated with depression
symptoms was high (70%) but, after adjustment for cardiovascular
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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risk factors, only a 23% increased risk remained. It is well known
that over a certain amount of time, the strength of the effect
of a given factor on disease occurrence may change because
the prevalence of its causal complement in various mechanisms
also changes.29 It is therefore likely that participants with chronic
diseases such as diabetes have different distributions of the other
component causes, i.e cardiovascular risk factors, compared with
the general population.
Strengths and study limitations
The large sample size and the life span perspective, together
with long follow-up are amongst the most important strengths
of this study. Furthermore, the HUNT catchment area has a low
net migration (<0.3% net migration/year) and close to complete
follow-up at the local hospitals.
Nevertheless, the study also has some important limitations.
Similar to other prospective studies of risk for HF associated with
symptoms of depression, we did not assess depression and anxi-
ety disorders, but relied on self-reported symptoms. The HADS
questionnaire, which was used in HUNT, does not mirror somatic
depressive symptoms such as fatigue, weight loss, and insomnia,
which greatly overlap with HF symptoms.15,22 However, by using
this approach, some depression cases with predominantly somatic
symptoms may go undetected. Thus, it is more likely that our esti-
mate for the association between symptoms of depression, anxiety,
and MSAD with future HF is underestimated than overestimated.
Even though we found no evidence of excess risk for HF in partici-
pants who reported symptoms of anxiety and depression in HUNT
1, ten years prior to baseline, compared with those who did not,
our study cannot conclude whether there is a dose–response rela-
tionship between the number of episodes of symptoms of anxiety
and depression, and HF risk.
Further, depressive symptoms have been shown to be associated
with low adherence to treatment, drug, and medical advice.1,39–42
The Norwegian prescription registry was established in 2004,
and the HUNT 2 study does not have access to reliable data
about all participants’ medications. It is important to distinguish
treatment by tricyclic antidepressant which are known to cause
adverse cardiovascular effects from by selective serotonin reup-
take inhibitors (SSRIs) that are associated with effects that are
favourable in lowering cardiovascular risk.43 Therefore, poor medi-
cal adherence might be a potential mechanism that remained unde-
tected in our study. However, in the only large-scale study of risk
for HF with major depressive disorder, the observed age-adjusted
risk of 1.21 (1.13–1.28) increased to 1.56 with adjustment for
psychotropics.17 The same US study also found a protective effect
of psycotropics for symptoms of anxiety and MSAD, where the
point estimate increased from 1.19 to 1.46 and 1.24 to 1.74,
respectively. Also for depressive symptoms, other studies indicate
that treatment including psychotropics44,45 protects depressed per-
sons for future cardiovascular disease risk rather than confounding
the relationship.
Increased neurohormonal stress activity and inflammation have
also been linked to development of depression.1 Symptoms of
depression may in turn up-regulate and worsen the neurohormonal ..
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.. regulation of heart rate, blood pressure, and obesity, which are
all central mechanisms in the development of HF.1,16,46–48 In
contrast, anxiety symptoms showed a weaker association with
future HF in the current cohort. It may be hypothesized that
low intensity anxiety, such as worry and tension, as measured by
HADS-A, activates proinflammatory cytokines or neurohormonal
stress activity less than diagnostic categories of anxiety, such as
panic disorders and agoraphobic disorder. These latter conditions
manifest with intense physiological activation and are found to
increase overall morbidity.49 Furthermore, symptoms of anxiety
often act as a precursor for depressive symptoms, and of the
two conditions depression is often found to be the largest driving
factor in mortality studies.39 Unfortunately, the HUNT study did
not analyse markers of increased neurohormonal activity, and
inflammatory activity was only analysed for a small subpopulation;
therefore, we were not able to test these hypothetical links
between depressive symptoms and future HF.
Identification and ascertainment of HF diagnostics might be
misclassified. However, the overall quality and reliability of the
hospital discharge registers of HF is high in Nordic Countries.27,50
In line with Nordic recommendations and to ensure optimal
precision, only those with a primary diagnosis of HF were included
in the analyses.25,27,50 From January 1995 to December 2008, a
total of 1958 patients (≥18 years of age) were diagnosed with HF
in the two hospitals of Nord-Trøndelag County. Of these, only
29 (1.6%) were diagnosed outside the Departments of Internal
Medicine/Cardiology. Thus, 98.4% of the total HF patients received
their hospital diagnosis in a setting where cardiologists were central
in the diagnostics, ensuring a high sensitivity and specificity. Data
from the Cause of Death Registry have somewhat lower reliability
than the hospital discharge register of the HF diagnosis,25 as
many of these deaths are probably sudden. However, even if we
do not know which proportion of the deaths were sudden, we
obtained essentially the same effect by restricting the study to
hospital-verified HF cases, and therefore it seems unlikely that the
lower reliability of HF deaths could explain our findings.
Conclusion
Symptoms of depression, but not symptoms of anxiety or MSAD,
were associated with increased risk for HF in a dose–response
manner in this general population sample. The increased risk
could not be directly explained by established cardiovascular risk
factors or by prevalent or incident AMI. Prevention and treatment
strategies for depressive symptoms might have the potential to
reduce development of cardiovascular disease, including HF, and
should therefore be carried out on a population level and in
primary care settings, not only in patients with established HF
or cardiovascular disorders. In both community51 and hospital
samples,52 anxiety often co-exists and worsens the course of
depressive symptoms, and it is recommended to consider both
conditions when planning appropriate management strategiesl.53
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